JP2011510654A - 有用な抗体を発現する雑種細胞の作成方法 - Google Patents

有用な抗体を発現する雑種細胞の作成方法 Download PDF

Info

Publication number
JP2011510654A
JP2011510654A JP2010545017A JP2010545017A JP2011510654A JP 2011510654 A JP2011510654 A JP 2011510654A JP 2010545017 A JP2010545017 A JP 2010545017A JP 2010545017 A JP2010545017 A JP 2010545017A JP 2011510654 A JP2011510654 A JP 2011510654A
Authority
JP
Japan
Prior art keywords
antibody
cells
nucleic acid
hybridoma
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510654A5 (enExample
Inventor
スコット・ケイ・デサイン
シャラド・ピー・アデカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of JP2011510654A publication Critical patent/JP2011510654A/ja
Publication of JP2011510654A5 publication Critical patent/JP2011510654A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010545017A 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法 Pending JP2011510654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6258408P 2008-01-28 2008-01-28
PCT/US2009/000562 WO2009105150A2 (en) 2008-01-28 2009-01-28 Method of making hybrid cells that express useful antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015009809A Division JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Publications (2)

Publication Number Publication Date
JP2011510654A true JP2011510654A (ja) 2011-04-07
JP2011510654A5 JP2011510654A5 (enExample) 2012-03-15

Family

ID=40986086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545017A Pending JP2011510654A (ja) 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Country Status (4)

Country Link
US (1) US8999707B2 (enExample)
EP (1) EP2242836B1 (enExample)
JP (2) JP2011510654A (enExample)
WO (1) WO2009105150A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8557575B2 (en) 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
WO2010003529A1 (en) * 2008-06-16 2010-01-14 University Of Zurich Method of providing immunoglobulin secreting b lymphocytes and human antibodies
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
US20160014600A1 (en) * 2014-07-10 2016-01-14 Bank Of America Corporation Identification of Potential Improper Transaction
US20160253708A1 (en) * 2015-02-26 2016-09-01 Dropbox, Inc. Method and system for efficiently serving upsell content based on complex user archetypes
JP2019506412A (ja) 2016-02-10 2019-03-07 ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
BR112021006431A2 (pt) 2018-10-02 2021-07-27 Immunome, Inc. anticorpos direcionados a epn1
WO2022150809A1 (en) 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
CN114350606A (zh) * 2022-01-05 2022-04-15 上海药明生物医药有限公司 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063415A2 (en) * 2005-08-23 2007-06-07 Iq Corporation Methods of producing stable b-lymphocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150991B2 (ja) * 1991-04-10 2001-03-26 協和醗酵工業株式会社 ハイブリドーマの製造法
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7491530B2 (en) 2001-12-18 2009-02-17 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP1692276B1 (en) * 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of inducing memory b cell development and terminal differentiation
US8557575B2 (en) * 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063415A2 (en) * 2005-08-23 2007-06-07 Iq Corporation Methods of producing stable b-lymphocytes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013058515; Ｊ　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１６９，　Ｎｏ．８, 20021015, ｐ．４２９８-４３０６ *
JPN6013058518; Ｊ　Ｉｍｍｕｎｏｌ　Ｍｅｔｈｏｄｓ． Ｖｏｌ．２９１，　Ｎｏ．１-２, 200408, ｐ．１０９-１２２ *
JPN6013058519; ＤＥＳＳＡＩＮ，　Ｓ．Ｋ．　ｅｔ　ａｌ．: 'ＳＥＳＳＩＯＮ　７：　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥＳ　Ｉ，　Ｕｓｅ　ｏｆ　ａ　ｎｏｖｅｌ　ｈｅｔｅｒｏ-ｈｙｂｒｉｄｏｍａ　ｍｅｔｈｏｄ　ｔｏ　ｃｌｏｎｅ　ｐｏｔｅｎｔ，　ｈｉｇｈ　ａｆｆｉｎ' ＨＡＨ　２００７　Ｓｅｃｏｎｄ　Ｃｉｒｃｕｌａｒ　ａｎｄ　Ｐｒｏｖｉｓｉｏｎａｌ　Ｃｏｎｆｅｒｅｎｃｅ　Ｐｒｏｇｒａｍ，　［ｏｎｌｉｎｅ］ , 200710 *
JPN6013058521; ＤＥＳＳＡＩＮ，　Ｓ．Ｋ．　ｅｔ　ａｌ．: 'Ｓｅｓｓｉｏｎ　７：　Ｉｎｆｅｃｔｉｏｕｓ　ｄｉｓｅａｓｅｓ　Ｉ，　Ｕｓｅ　ｏｆ　ａ　ｎｏｖｅｌ　ｈｅｔｅｒｏ-ｈｙｂｒｉｄｏｍａ　ｍｅｔｈｏｄ　ｔｏ　ｃｌｏｎｅ　ｐｏｔｅｎｔ，　ｈｉｇｈ　ａｆｆｉｎ' Ｈｕｍａｎ　Ａｎｔｉｂｏｄｉｅｓ Ｖｏｌ．１６，　Ｎｏ．１-２, 2007, ｐ．２８-２９ *

Also Published As

Publication number Publication date
WO2009105150A3 (en) 2010-03-18
JP5923186B2 (ja) 2016-05-24
US8999707B2 (en) 2015-04-07
US20110002937A1 (en) 2011-01-06
WO2009105150A2 (en) 2009-08-27
JP2015083016A (ja) 2015-04-30
EP2242836A4 (en) 2011-05-25
EP2242836B1 (en) 2015-05-20
EP2242836A2 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
JP5923186B2 (ja) 有用な抗体を発現する雑種細胞の作成方法
JP6799101B2 (ja) クローディンを発現するガン疾患を処置するための剤
TWI329649B (en) Immunoglobulins
CN104334580B (zh) 抗sez6抗体及使用方法
US20050014931A1 (en) Human antipneumococcal antibodies from non-human animals
WO2020043188A1 (zh) 抗cd47抗体及其应用
TWI422593B (zh) An anti-FGF23 antibody and a pharmaceutical composition containing the same
US9089557B2 (en) Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse
AU2018202199A1 (en) Clostridium difficile antibodies
TW201231066A (en) Pan-HER antibody composition
US8557575B2 (en) Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US20250255960A1 (en) Anti-cd70 nanoantibody and use thereof
CN116903757B (zh) Cd70纳米抗体和双靶向嵌合抗原受体
TW202115122A (zh) 抗b7-h3抗體及其應用
CN111518208A (zh) 抗cd47抗体及其应用
KR20220117267A (ko) Tgf-베타-rii 결합 단백질
CN117999284A (zh) 靶向tigit的单克隆抗体
JP2024517985A (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
Chin et al. Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell
WO2014138733A2 (en) Compositions and methods for making human antibodies
EP2548891A1 (en) Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
WO2025201517A1 (zh) 抗cd93抗体、其抗原结合片段及其应用
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
HK40088437B (en) Anti-cd70 nanoantibody and use thereof
HK40088437A (en) Anti-cd70 nanoantibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141007